Cyclopharm Limited (ASX:CYC)

$1.66

right-arrow Created with Sketch. -0.02 (-1.19%)
MCAP $156.8M
Last trade 15.15pm 09/12/2021 20mins delayed

Latest Announcements

01/12/2021CYCCyclopharm Limited
01/12/2021CYCCyclopharm Limited
103
MCap
09/11/2021CYCCyclopharm Limited
28/10/2021CYCCyclopharm Limited
23/08/2021 Price SensitivePSCYCCyclopharm Limited
23/08/2021CYCCyclopharm Limited
23/08/2021 Price SensitivePSCYCCyclopharm Limited
10/08/2021CYCCyclopharm Limited

Company Overview

Cyclopharm Limited is an Australia-based company engaged in the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development. It provides diagnostic imaging services specializing in lung health. The Company through its medical device and pharmaceutical products under the name of Technegas, which has become the industry in diagnostic functional lung imaging technology. It distributes its products in approximately 60 countries throughout the world with over 1500 nuclear medicine departments utilizing Technegas. The Company formed a joint venture with Alfred Health Solutions and Macquarie University Hospital to provide various imaging services on-site at the hospital. The Macquarie Medical Imaging (MMI) offers a range of diagnostic radiology, interventional radiology, nuclear medicine and molecular imaging services for inpatient and outpatients. Its Ultralute is a device that extends the useful life of Molybdenum-99 (Mo-99) generators.

CYC in the news

Cyclopharm (CYC) is expecting to report a record half-year revenue result of…
Cyclopharm (CYC) shares drop 35 per cent after the US Food and…
Cyclopharm (CYC) has provided an update on the new drug application (NDA)…
Cyclopharm (CYC) is set to receive a $3.1 million research and development…

Search Previous Announcements